Testing Erlotinib in a Mouse Model of Rhabdomyosarcoma
Author Information
Author(s): Abraham Jinu, Nelon Laura D., Kubicek Courtney B., Kilcoyne Aoife, Hampton Sheila T., Zarzabal Lee Ann, Giles Francis J., Michalek Joel E., Rubin Brian P., Keller Charles
Primary Institution: Oregon Health & Science University
Hypothesis
Can Erlotinib effectively treat alveolar rhabdomyosarcoma in a mouse model?
Conclusion
Erlotinib had no effect on tumor progression in the mouse model of alveolar rhabdomyosarcoma.
Supporting Evidence
- Erlotinib did not significantly reduce tumor volume compared to controls.
- Mice treated with Erlotinib experienced a 10–20% loss in body weight.
- EGFR was expressed in the tumors, but the drug did not have the expected therapeutic effect.
Takeaway
The study tested a cancer drug called Erlotinib on mice with a specific type of cancer, but it didn't help the mice get better.
Methodology
Mice were treated with Erlotinib and tumor growth and body weight were monitored over time.
Limitations
Erlotinib may not have been absorbed well orally, affecting its efficacy.
Participant Demographics
Mice with genetically engineered alveolar rhabdomyosarcoma.
Statistical Information
P-Value
0.21
Statistical Significance
p=0.21
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website